Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + carfilzomib + dexamethasone versus carfilzomib + dexamethasone in relapsed or refractory multiple myeloma
2017-001940-37Phase 3Unknown
- Sponsor
- Sanofi
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Isatuximab + carfilzomib + dexamethasone with Carfilzomib + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
isatuximabcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-001940-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001940-37.